| Project/Area Number |
26670023
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Juntendo University (2015-2017)
St. Luke's International University (2014) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | がん幹細胞 / ZnT1 / モノクローナル抗体 / 大腸がん / 乳がん / フローサイトメトリー / 非対称分裂 / ZnT1、、非対称分裂 / モのクロ－ナル抗体 |
|---|
| Outline of Final Research Achievements |
Cancer stem cells are important subjects to understand the treatment resistance, latency and recurrence of cancer and to improve therapy. However, it was not easy to identify them in histological and cytological context. The mechanism how they give rise should be investigated with appropriate surface markers, which was not available. We have recently prepared a monoclonal antibody against ZnT1, a cancer stem cell surface marker candidate discovered by genetic analysis. Our specific aim was to visualize the developmental state of cancer stem cells by the use of the antibody. However, after careful investigations conducted under the present project, we concluded that the anti-ZnT1 antibody positive cell population was not identical to cancer stem cell populations identified by other methods. The expression status of this molecule did not correlate with the treatment resistance of cancer. However, we found that the developed monoclonal antibody is useful as a tool to analyze ZnT1.
|
